Erich SchlickChairman

Erich Schlick is general partner with Wellington Partners in Munich. Prior to venture capital, Erich spent 15 years with BASF Pharma Knoll AG, 10 years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D. During this time, he obtained worldwide registrations for five products in cardiovascular, metabolic and pain indications. In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira. Erich studied medicine and specialised in pharmacology. He holds a professorship of immunopharmacology at the University of Heidelberg/Mannheim.

Claude Claret

Claude Claret, 55 years old, holds a MBA and a PhD in Pharmacy. Dr. Claret started his career with Allergan-AMO where he spent 10 years as Marketing Director. He was responsible for the European glaucoma pre-launches. He then joined in 1993 Transphyto, a R&D company, as Director Business Development; through his activities, Dr. Claret participated to the creation of Laboratoires Théa where he was also General Manager for 8 years. He then started his own company, MC Développements, providing consulting services for marketing, developing, in- or out-licensing pharmaceutical products. Since 2003, Dr. Claret is the owner and General Manager of Horus Pharma, a growing independent laboratory specialised in ophthalmology and developing drugs, devices and production processes.

Michel Habib

Michel Habib is Venture Partner with Agate Medical Investments LP and the Founder & CEO of Matar Capital Advisors, a Venture Boutique. Prior to that he served as Director Business Development at Elron Electronic Industries, part of the IDB group (NASDAQ ELRN) where he led Medical Device investments (Nulens, Brainsgate, Impliant etc) and served as BOD of Elbit Vision Systems, Nulens, 3DV Systems, KIT, Elron Telesoft & others. Prior to Elron Michel established and managed the investment banking activity of ING Barings, the London-Amsterdam based investment arm of ING Group, in Israel. Prior to that Michel served as VP Investment Banking at Cukierman & Co. Formerly Michel served as Israel's Economic Consul to New England, Boston, & as Commercial Attache to Seoul, South Korea. Michel holds a BSc in Aeronautical Engineering from the Technion - Israel Institute of Technology and he is member of the Technion Alumni ‘100 Club’.

 André J. Mueller

André J. Mueller, born in 1944 is a citizen of Switzerland as well as Belgium. André holds a degree in chemical Engineering and a master in business economics from the Geneva University (Switzerland) as well as a MBA from the INSEAD Business School based in Fontainebleau, France. Mr Mueller started his career with CIBA and Sandoz Ltd (now Novartis) and has been associated over the last 30 years with numerous venture capital backed biotech and medtech enterprises. André was the first CFO at Biogen and part as a Founding Partner of Actelion Ltd and served as CFO and Board member. He is currently Chairman of the Board of Addex Therapeutics (SIX: ADXN) and advisor to several Swiss start-up enterprises.

 Lincoln Chee Wang Jin

Dr Lincoln Chee is a Venture Partner and leads the healthcare and life science practice at Vertex Venture Holdings, a venture subsidiary of Temasek Holdings. He is also an Operating Partner for Advent International Private Equity in Healthcare. Prior to venture capital, Dr Chee was Chief Executive Officer and board member at Quality Healthcare Asia, Hong Kong’s first publicly listed and leading healthcare company. In addition Dr Chee led investments and served on the boards of Arana Therapeutics in Australia and Biosensors International Singapore.  He previously held various committee positions with Hong Kong Government Food and Health Bureau and Trade Development Council.  In 2009, Dr Chee was selected as outstanding entrepreneur of Hong Kong in the Asia Pacific Entrepreneurship Awards.

Jean-Marc Wismer

Jean-Marc brings 25 years experience in international growth management and financing. Formerly executive with Silicon Microstructures Inc. and Medtronic, COO of Lysis, CEO and founder of Neocast. Since 2003, Jean-Marc is active as a business consultant and interim manager for innovative high-tech companies such as Innovative Silicon, Spinetix, Axsionics, Nexthink, or Mnemis. He is also a consultant and financial expert with the CTI start-up Swiss federal organization, lecturer with Venturelab and Master of Technology/EPFL, and is jury member with Venturekick. Jean-Marc holds a MSc in Electrical Engineering from EPFL and MBA from IMD.